ENDOCRINE–MICROVASCULAR COUPLING

by

IN THE DEVELOPMENT OF DIASTOLIC DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION

Editorial Note

This article was originally published in the journal Zarubezhnaya Meditsina i My in February 2025 (No. 1–2025). The Editorial Board of the International Journal of Interdisciplinary Research approved the republication of this work due to its interdisciplinary relevance to endocrinology, cardiology, myocardial microcirculation, and clinical gerontology. The text is reproduced with the author’s permission and without substantive changes compared to the original publication.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is among the most prevalent forms of heart failure in older populations and in patients with cardiometabolic and endocrine disorders. Increasing evidence supports a central role of myocardial microvascular dysfunction and endocrine–metabolic factors in the development of diastolic dysfunction, even in the absence of significant epicardial coronary artery disease.
This article provides an integrative analysis of the concept of endocrine–microvascular coupling, whereby hormonal and metabolic disturbances are viewed as key modulators of myocardial microcirculation and diastolic cardiac function. Pathophysiological mechanisms, clinical manifestations, advanced diagnostic approaches, and preventive strategies aimed at
early identification and slowing of HFpEF progression in patients with age-associated and cardiometabolic disorders are discussed.

Keywords:

diastolic dysfunction, HFpEF, myocardial microcirculation, endocrine disorders, insulin resistance, endothelial dysfunction, vascular aging.

Author: Natalia V. Brailova
ORCID: 0009-0002-2155-411X

International Journal of Interdisciplinary Research
Volume 6, Issue 1 (2025)

Peer Reviewer (Acknowledged): Boris Karsakov
ORCID: 0009-0006-4851-6366

DOI: pending

Full Text (PDF)

ENDOCRINE–MICROVASCULAR-COUPLING

References

  1. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263–271.
  2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal. 2011;32(6):670–679.
  3. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2020;17(9):559–573.
  4. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73–90.
  5. Obokata M, Reddy YNV, Borlaug BA. The role of echocardiography in heart failure with preserved ejection fraction: what do we want from imaging? Heart Failure Clinics. 2019;15(2):241–256.
    Myocardial Microcirculation and Coronary Microvascular Dysfunction
  6. Camici PG, Crea F. Coronary microvascular dysfunction. The New England Journal of Medicine. 2007;356(8):830–840.
  7. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options. Journal of the American College of Cardiology. 2018;72(21):2625–2641.
  8. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129(24):2518–2527.
  9. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. European Heart Journal. 2018;39(10):840–849.
    PET Imaging and Quantitative Myocardial Blood Flow
  10. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease: role of PET myocardial perfusion imaging. Journal of the American College of Cardiology. 2013;62(18):1639–1653.
  11. Murthy VL, Lee BC, Sitek A, et al. Quantitative myocardial blood flow assessment with PET: an overview. Journal of Nuclear Cardiology. 2018;25(2):610–625.
  12. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve and adverse cardiovascular events. Journal of the American College of Cardiology. 2015;66(4):377–387.
    Cardiac MRI, Perfusion, and Myocardial Fibrosis
  13. Schelbert EB, Fonarow GC, Bonow RO, Butler J. Imaging heart failure with preserved ejection fraction: diagnostic and mechanistic insights. JACC: Cardiovascular Imaging. 2014;7(4):413–426.
  14. Schelbert EB, Messroghli DR. State of the art: clinical applications of cardiac T1 mapping. Radiology. 2016;278(3):658–676.
  15. Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease. JACC: Cardiovascular Imaging. 2013;6(4):475–484.
  16. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation. Journal of the American College of Cardiology. 2018;72(24):3158–3176.
    Endocrine and Metabolic Mechanisms in HFpEF
  17. Reaven GM. Insulin resistance and human disease. Diabetes. 1988;37(12):1595–1607.
  18. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. The Lancet. 2012;380(9841):601–610.
  19. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circulation Research. 2012;110(8):1097–1108.
  20. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circulation Research. 2018;123(7):849–867.
    Inflammation, Endothelium, and Remodeling
  21. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
  22. Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circulation Research. 2018;123(7):825–848.
  23. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clinical Science (London). 2011;120(9):357–375.
  24. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews Cardiology. 2018;15(9):505–522.
    Biomarkers, Fibrosis, and Clinical Stratification
  25. Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril/valsartan with cardiac structure and function in HFpEF. JAMA. 2019;322(11):1085–1095.
  26. Bayes-Genis A, Zamora E, Lupón J. Galectin-3 in heart failure: linking fibrosis, remodeling, and inflammation. Heart Failure Clinics. 2018;14(1):73–81.
  27. Santhanakrishnan R, Wang N, Larson MG, et al. Circulating biomarkers of fibrosis and risk of heart failure with preserved ejection fraction. Journal of the American College of Cardiology. 2017;70(24):2986–2997.